Florida Cancer Specialists & Research Institute Welcomes Nikita Jain, MD to Practice

Statewide Practice Expands Clinical Team in Manatee County

FORT MYERS, Fla., April 1, 2026 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) welcomes board-certified medical oncologist and hematologist Nikita Jain, MD to the statewide practice. Dr. Jain will provide care to patients at the FCS Bradenton Cancer Center at 3630 Manatee Ave W, Bradenton, FL 34205.

David Wenk, MD, FCS assistant managing physician, said, "Dr. Jain's clinical expertise, paired with her focus on precision medicine and patient-centered care, strengthens our ability to deliver advanced, individualized treatment options to patients in Manatee County. Her collaborative approach and commitment to building strong patient relationships align closely with the mission of FCS."

Dr. Jain earned her medical degree from SMC, India. She completed her residency in internal medicine at Northwestern Medicine, Illinois, followed by a fellowship in hematology and medical oncology at the University of Louisville in Louisville, Kentucky. She is board certified in medical oncology, hematology and internal medicine.

Prior to joining FCS in 2026, Dr. Jain practiced in Sheboygan, Wisconsin. She is a member of the American Society of Clinical Oncology and the American Society of Hematology.

About Florida Cancer Specialists & Research Institute, LLC: (FLCancer.com)
For more than 40 years, Florida Cancer Specialists & Research Institute (FCS) has embraced innovation to deliver world-class care and drive the dramatic transformation of oncology care through its robust clinical research program.

FCS provides patients with access to a wide range of clinical trials, positioning it as a leader in research among private oncology practices in Florida and across the country. Through its robust clinical research program with Sarah Cannon Research Institute (SCRI) and a suite of independent site management programs, with advanced clinical trial matching technology, FCS offers patients innovative therapies close to home. Each year, FCS conducts more than 180 active clinical trials that directly elevate patient care and accelerate progress in oncology. Many of the cancer drugs approved by the FDA in the U.S over the past decade were accessible to patients at FCS through clinical trial participation before receiving approval.

Our outstanding team of highly trained and dedicated physicians is committed to delivering tailored treatment plans that make the best use of cutting-edge precision oncology advancements to enhance patient outcomes.

SOURCE Florida Cancer Specialists & Research Institute